Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015
- PMID: 29126310
- DOI: 10.1093/cid/cix993
Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015
Abstract
Background: In 2005, meningococcal conjugate vaccine (MenACWY) was recommended for routine use among adolescents aged 11-18 years. This report describes the epidemiologic features of meningococcal disease and trends in meningococcal disease incidence following MenACWY introduction in the United States.
Methods: Incidence rates and case-fatality ratios by age group and serogroup during 2006-2015 were calculated using data from the National Notifiable Diseases Surveillance System (NNDSS); changes in incidence during this time were evaluated. Additionally, 20-year trends (1996-2015) in age- and race-standardized incidence were examined using data from Active Bacterial Core surveillance (ABCs).
Results: During the years 2006-2015, 7924 cases of meningococcal disease were reported to NNDSS, resulting in an average annual incidence of 0.26 cases per 100000 population; 14.9% of cases were fatal. Among cases with serogroup information, 2290 (35.8%) were serogroup B, 1827 (28.5%) were serogroup Y, 1457 (22.8%) were serogroup C, 436 (6.8%) were serogroup W, and 392 (6.1%) were other serogroups. The incidence of serogroups A, C, W, and Y combined declined 76% among persons aged 11-20 years from 2006-2010 to 2011-2015 (P < .0001). From 1996 through 2015, the incidence of meningococcal disease declined among all age groups and predominant serogroups.
Conclusions: Declines in meningococcal disease incidence in the United States have been observed among all age groups and predominant serogroups (B, C, and Y). Reductions in the incidence of meningococcal disease due to serogroups A, C, W, and Y among adolescents suggest an impact of the MenACWY vaccine program in this age group.
Similar articles
-
Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.J Infect Dis. 2015 Jun 15;211(12):1887-94. doi: 10.1093/infdis/jiu842. Epub 2015 Jan 2. J Infect Dis. 2015. PMID: 25556253
-
Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.JAMA Pediatr. 2020 Sep 1;174(9):843-851. doi: 10.1001/jamapediatrics.2020.1990. JAMA Pediatr. 2020. PMID: 32687590 Free PMC article.
-
Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.Vaccine. 2015 Oct 13;33(42):5678-5683. doi: 10.1016/j.vaccine.2015.08.023. Epub 2015 Aug 20. Vaccine. 2015. PMID: 26299749
-
Prospects for vaccine prevention of meningococcal infection.Clin Microbiol Rev. 2006 Jan;19(1):142-64. doi: 10.1128/CMR.19.1.142-164.2006. Clin Microbiol Rev. 2006. PMID: 16418528 Free PMC article. Review.
-
Evolving meningococcal immunization strategies.Expert Rev Vaccines. 2015 Apr;14(4):505-17. doi: 10.1586/14760584.2015.979799. Epub 2014 Dec 10. Expert Rev Vaccines. 2015. PMID: 25494168 Review.
Cited by
-
Risk Factors for Serogroup B Meningococcal Disease Among College Students.Open Forum Infect Dis. 2023 Dec 2;10(12):ofad607. doi: 10.1093/ofid/ofad607. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38149105 Free PMC article.
-
Differences in meningococcal disease incidence by health insurance type and among persons experiencing homelessness-United States, 2016-2019.PLoS One. 2023 Oct 19;18(10):e0293070. doi: 10.1371/journal.pone.0293070. eCollection 2023. PLoS One. 2023. PMID: 37856507 Free PMC article.
-
Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.J Infect. 2022 Dec;85(6):611-622. doi: 10.1016/j.jinf.2022.10.022. Epub 2022 Oct 20. J Infect. 2022. PMID: 36273639 Free PMC article. Review.
-
Next Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases.Genes (Basel). 2022 Aug 31;13(9):1566. doi: 10.3390/genes13091566. Genes (Basel). 2022. PMID: 36140733 Free PMC article. Review.
-
Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.Hum Vaccin Immunother. 2022 Nov 30;18(6):2099142. doi: 10.1080/21645515.2022.2099142. Epub 2022 Aug 10. Hum Vaccin Immunother. 2022. PMID: 35947774 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical